Her2 Expression in Circulating Tumor Cells Is Associated with Poor Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer.
HER2 (ERBB2)
androgen receptor signaling inhibitors (ARSI)
androgen receptor splice variant 7 (AR-V7)
circulating tumors cells (CTCs)
highly sensitive assay
liquid profiling
metastatic castration resistant prostate cancer (mCRPC)
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
29 Nov 2021
29 Nov 2021
Historique:
received:
26
10
2021
revised:
22
11
2021
accepted:
23
11
2021
entrez:
10
12
2021
pubmed:
11
12
2021
medline:
11
12
2021
Statut:
epublish
Résumé
HER2-dependent signaling may support the development of metastatic castration-resistant prostate cancer (mCRPC) by activating androgen receptor signaling through ligand-independent mechanisms. From 41 mCRPC patients (including 31 treated with Androgen Receptor Signaling Inhibitors [ARSI]), Circulating Tumor Cells (CTCs) were prospectively enriched with AdnaTest platform and analyzed with a multiplexed assay for
Identifiants
pubmed: 34885125
pii: cancers13236014
doi: 10.3390/cancers13236014
pmc: PMC8656805
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ligue Nationale Contre le Cancer
ID : cd69
Références
Int J Urol. 2009 Apr;16(4):369-74
pubmed: 19207111
Ann Oncol. 2008 Feb;19(2):269-75
pubmed: 17998285
Clin Cancer Res. 2004 Jul 15;10(14):4742-5
pubmed: 15269147
Cancer Res. 2017 Jan 1;77(1):74-85
pubmed: 27793843
Clin Cancer Res. 2006 Jan 1;12(1):123-30
pubmed: 16397033
Ann Oncol. 2020 Sep;31(9):1119-1134
pubmed: 32593798
J Biol Chem. 2003 Dec 19;278(51):50902-7
pubmed: 14555644
Urol Oncol. 2013 Jan;31(1):82-6
pubmed: 21396844
Cancer Treat Rev. 2015 Dec;41(10):884-92
pubmed: 26342718
N Engl J Med. 2014 Sep 11;371(11):1028-38
pubmed: 25184630
Eur Urol Oncol. 2021 Aug;4(4):609-617
pubmed: 31676281
PLoS One. 2014 Jun 17;9(6):e99525
pubmed: 24937171
Clin Cancer Res. 2010 Mar 1;16(5):1553-60
pubmed: 20179235
Hum Pathol. 2006 Sep;37(9):1137-44
pubmed: 16938518
Clin Cancer Res. 2005 Mar 1;11(5):1704-12
pubmed: 15755991
Br J Cancer. 2019 Jul;121(3):237-248
pubmed: 31209328
Int J Biochem Cell Biol. 2009 Mar;41(3):603-14
pubmed: 18692155
Prostate. 2012 May 15;72(7):777-88
pubmed: 21932427
J Biol Chem. 2010 Jul 30;285(31):23598-606
pubmed: 20498373
Int J Urol. 2006 Sep;13(9):1197-201
pubmed: 16984552
Asian Pac J Cancer Prev. 2015;16(15):6615-9
pubmed: 26434884
Endocr Relat Cancer. 2007 Sep;14(3):601-11
pubmed: 17914091
J Clin Oncol. 2016 Apr 20;34(12):1402-18
pubmed: 26903579
Oncotarget. 2018 Jun 29;9(50):29403-29413
pubmed: 30034626
Mol Cell Endocrinol. 2012 Mar 5;350(1):107-17
pubmed: 22155408
Cell Signal. 2015 Nov;27(11):2261-71
pubmed: 26257301
Cancer Res. 2000 Dec 15;60(24):6841-5
pubmed: 11156376
Clin Cancer Res. 2016 Jul 15;22(14):3672-82
pubmed: 26936914
Tumori. 2007 Sep-Oct;93(5):467-72
pubmed: 18038879
Cancer Res. 2016 Jun 1;76(11):3397-410
pubmed: 27197172
Oncotarget. 2015 Apr 20;6(11):9086-98
pubmed: 25871401
Clin Chem. 2004 May;50(5):826-35
pubmed: 14988224
Br J Cancer. 2004 Jan 26;90(2):443-8
pubmed: 14735191